Skip to main content
SpringerLink
Log in

State of art in antibacterial susceptibility ofBordetella pertussis and antibiotic treatment of pertussis

  • Review
  • Published:
Infection Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Hoppe, J. E., Haug, A.: Antimicrobial susceptibility ofBordetella pertussis (Part I). Infection 16 (1988) 126–130.

    Article  PubMed  CAS  Google Scholar 

  2. Hoppe, J. E., Haug, A.: Treatment and prevetion of pertussis by antimicrobial agents (part II). Infection 16 (1988) 148–152.

    Article  PubMed  CAS  Google Scholar 

  3. Kurzynski, T. A., Boehm, D. M., Rott-Petri, J. A., Schell, R. F., Allison, P. E.: Antimicrobial susceptibilities ofBordetella species isolated in a multicenter pertussis surveillance project. Antimicrob. Agents Chemother. 32 (1988) 137–140.

    PubMed  CAS  Google Scholar 

  4. Hardy, D. J., Hensey, D. M., Beyer, J. M., Vojtko, C., McDonald, E. J., Fernandes, P. B.: Comparativein vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32 (1988) 1710–1719.

    PubMed  CAS  Google Scholar 

  5. Simon, C., Simon, M., Plieth, C.:In vitro activity of flomoxef in comparison to other cephalosporins. Infection 16 (1988) 131–134.

    Article  PubMed  CAS  Google Scholar 

  6. Tsuji, M., Ishii, Y., Ohno, A., Miyazaki, S., Yamaguchi, K.:In vitro andin vivo antibacterial activities of S-1090, a new oral cephalosporin Antimicrob. Agents Chemother. 39 (1995) 2544–2551.

    CAS  Google Scholar 

  7. Appleman, M. E., Hadfield, T. L., Gaines, J. K., Winn, R. E.: Susceptibility ofBordetella pertussis to five quinolone antimicrobic drugs. Diagn. Micrboil. Infect. Dis. 8 (1987) 131–133.

    Article  CAS  Google Scholar 

  8. Swanson, R. N., Hardy, D. J., Chu, D. T. W., Shipkowitz, N. L., Clement, J. J.: Activity of temafloxacin against respiratory pathogens. Antimicrob Agents Chemother. 35 (1991) 423–429.

    PubMed  CAS  Google Scholar 

  9. Miyazaki, S., Domon, H., Tateda, K., Ohno, A., Ishii, Y., Matsumoto, T., Furuya, N., Yamaguchi, K.:In vitro andin vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections. Antimicrob. Agents Chemother. 41 (1997) 2582–2585.

    PubMed  CAS  Google Scholar 

  10. Hoppe, J. E., Eichhorn, A.: Activity of new macrolides againstBordetella pertussis andBordetella parapertussis. Eur. J. Clin. Microbiol. Infect. Dis. 8 (1989) 653–654.

    Article  PubMed  CAS  Google Scholar 

  11. Hoppe, J. E., Müller, J.:In vitro susceptibilities ofBordetella pertussis andBordetella parapertussis to six new oral cephalosporins. Antimicrob. Agents Chemother. 34 (1990) 1442–1443.

    PubMed  CAS  Google Scholar 

  12. Hoppe, J. E., Simon, C. G.:In vitro susceptibilities ofBordetella pertussis andBordetella parapertussis to seven fluoroquinolones. Antimicrob. Agents Chemother 34 (1990) 2287–2288.

    PubMed  CAS  Google Scholar 

  13. Hoppe, J. E., Bryskier, A.:In vitro susceptibilities ofBordetella pertussis andBordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob. Agents Chemother. 42 (1998) 965–966.

    PubMed  CAS  Google Scholar 

  14. Hoppe, J. E., Rahimi-Galougahi, E., Seibert, G.:In vitro, susceptibilities ofBordetella pertussis andBordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem, Antimicrob. Agents Chemother. 40 (1996) 807–808.

    PubMed  CAS  Google Scholar 

  15. Doucet-Populaire, F., Pangon, B., Doermann, H. P., Boudjadja, A., Ghnassia, J. C.:In vitro activity of a new fluoroquinolone BAY 12-8039 in comparison with ciprofloxacin and macrolides againstBordetella pertussis. Abstr. F-145, 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997, p. 170.

  16. Hoppe, J. E., Dalhoff, A., Pfründer, D.:In vitro susceptibilities ofBordetella pertussis andBordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin. Antimicrob. Agents Chemother. (1998) in press.

  17. Banernfeind, A., Jungwirth, R.: Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten. loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil. Infection 19 (1991) 353–362.

    Article  Google Scholar 

  18. Bauernfeind, A., Schweighart S., Eberlein, E., Jungwirth, R.:In vitro activity and stability against beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE 2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection 19 (Suppl. 5) (1991) S264-S275.

    Article  PubMed  CAS  Google Scholar 

  19. Hoppe, J. E., Tschirner, T.: Comparison of media for agar dilution susceptility testing ofBordetella pertussis andBordetella parapertussis, Eur. J. Clin. Microbiol. Infect. Dis 14 (1995) 775–779.

    Article  PubMed  CAS  Google Scholar 

  20. Barker, J., Farrell, I. D.: The effect of charcoal, on MICs forLegionella. J. Antimicrob. Chemother. 17 (1986) 127.

    Article  PubMed  CAS  Google Scholar 

  21. Lewis, K., Saubolle, M. A., Tenover, F. C., Rudinsky, M. F., Barbour, S. D., Cherry, J. D.: Pertussis caused by an erythromycin-resistant strain ofBordetella pertussis. Pediatr. Infect. Dis. J 14 (1995) 388–391.

    PubMed  CAS  Google Scholar 

  22. Korgenski, E. K., Daly, J. A.: Surveillance and detection of erythromycin resistance inBordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States. J. Clin. Microbiol. 35 (1997) 2989–2991.

    PubMed  CAS  Google Scholar 

  23. Bergogne-Bérézin, E.: Interpretation of pharmacologic data in respiratory tract infections. Int. J. Antimicrob. Agents 3 (1993) S3-S14.

    Article  PubMed  Google Scholar 

  24. Field, L. H., Parker, C. D.: Antibiotic susceptibility testing ofBordetella pertussis. Am. J. Clin. Pathol. 74 (1980) 312–316.

    PubMed  CAS  Google Scholar 

  25. Ellner, P. D., Neu, H. C.: The inhibitory quotient. JAMA 256 (1981) 1575–1578.

    Article  Google Scholar 

  26. Hewlett, E. L.: Pertussis: current concepts of pathogenesis and prevention. Pediatr. Infect. Dis. J. 16 (1997) S78-S84.

    Article  PubMed  CAS  Google Scholar 

  27. Hoppe, J. E., Erythromycin Study Group: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. Pediatr. Infect. Dis. J. 11 (1992) 189–193.

    Article  PubMed  CAS  Google Scholar 

  28. Brun, Y., Forey, F., Gamondes, J. P., Tebib, A., Brune, J., Fleurette J.: Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxicillin. J. Antimicrob. Chemother. 8 (1981) 459–466.

    Article  PubMed  CAS  Google Scholar 

  29. Bass, J. W.: Pertussis: current status of prevention and treatment. Pediatr. Infect. Dis. 4 (1985) 614–619.

    PubMed  CAS  Google Scholar 

  30. Halperin, S. A., Bortolussi, R., Langley, J. M., Miller, B., Eastwood, B. J.: Seven days of erythromycin estolate is as effective as fourteen days for the treatment ofBordetella pertussis infections. Pediatrics 100 (1997) 65–71.

    Article  PubMed  CAS  Google Scholar 

  31. Granström, G., Sterner, G., Nord, C. E., Granström, M.: Use of erythromycin to prevent pertussis in newborns of mothers with pertussis. J. Infect. Dis., 155 (1987) 1210–1214.

    PubMed  Google Scholar 

  32. Sprauer, M. A., Cochi, S. L., Zell, E. R., Sutter, R. W., Mullen, J. R., Englender, S. J., Patriarca, P. A.: Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am. J. Dis. Child 146 (1992) 177–181.

    PubMed  CAS  Google Scholar 

  33. De Serres, G., Boulianne, N., Duval, B.: Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr. Infect. Dis. J. 14 (1995) 969–975.

    PubMed  Google Scholar 

  34. Halperin, S. A., Bortolussi, R. Langley, J. M., Miller, B. Eastwood, B. J.: Erythromycin chemoprophylaxis in household contacts of children with pertussis. Abstr. K94, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996, p. 267.

  35. Rimoldi, R., Mangiarotti, P., de Rose, V., Nonis, A., Bertoletti, R., Gialdroni Grassi, G.: Penetration of roxithromycin into bronchial secretions. Br. J. Clin. Pract. 42 (Suppl. 55) (1988) 74–77.

    Google Scholar 

  36. Aoyama, T., Sunakawa, K., Iwata, S., Takeuchi, Y., Fujii, R.: Efficaty of short-term treatment of pertussis with clarithromycin and azith romycin. J. Pediatr. 129 (1996) 761–764.

    Article  PubMed  CAS  Google Scholar 

  37. Bace, A., Kuzmanovic, N., Zrnic, T. Pertussis: simple and short therapy with azithromycin. Abstr. 6.04, 4th International Conference on Macrolides, Azalides, Streptogramins, Ketolides, 1998, p. 58.

  38. Hoppe, J. E.: Update on epidemiology, diagnosis, and treatment of pertussis. Eur. J. Clin. Microbiol. Infect. Dis. 15 (1996) 189–193.

    Article  PubMed  CAS  Google Scholar 

  39. Miyazaki, S., Miyazaki, Y., Tsuji, A., Nishida, M., Goto, S.:In vitro antibacterial activity of ME1207, a new oral cephalosporin. Antimicrob. Agents Chemother. 35 (1991) 1691–1694.

    CAS  Google Scholar 

  40. Asahara, M., Tsuji, A., Goto, S., Masuda, K., Kiuchi, A.:In vitro andin vivo activities of QA-241, a new tricyclic quinolone derivative. Antimicrob. Agents Chemother. 33 (1989) 1144–1152.

    CAS  Google Scholar 

  41. Thys, J. P.: Quinolones in the treatment of bronchopulmonary infections. Rev. Infect. Dis. 10 (Suppl. 1) (1988) S212-S217.

    PubMed  Google Scholar 

  42. Nakamori, Y., Tsuboi, E., Narui, K., Nakatani, T., Nakata, K.: Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory infections. Jpn. J. Antibiot. 45 (1992) 539–547.

    PubMed  CAS  Google Scholar 

  43. Burkhardt, J. E., Walterspiel, J. N., Schaad, U. B.: Quinolone arthropathy in animals versus children. Clin. Infect. Dis. 25 (1997) 1196–1204.

    Article  PubMed  CAS  Google Scholar 

  44. Hoppe, J. E., Halm, U., Hagedorn, H. J., Kraminer-Hagedorn, A.: Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis. Infection 17 (1989) 227–231.

    Article  PubMed  CAS  Google Scholar 

  45. Felmingham, D., Robbins, M. J., Leakey, A., Cooke, R., Dencer, C., Salman, H., Ridgway, G. L., Grüneberg, R. N., Bryskier, A.: The comparativein vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates. Abstr. F-116 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997, p. 166.

  46. Tsuji, M., Ishii, Y., Ohno, A., Miyazaki, S., Yamaguchi, K.:In vitro andin vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42 (1998) 94–99.

    PubMed  CAS  Google Scholar 

  47. Bauernfeind, A., Jungwirth, R., Eberlein, E.: RU 29 246, the active compound of the cephalosporin produrg-ester HR 916. J. Antibiot. 45 (1992) 505–520.

    PubMed  CAS  Google Scholar 

  48. Bauernfeind, A.: Comparativein vitro activities of the new quinolone. Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J. Antimicrob. Chemother. 31 (1993) 505–522.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätskinderklinik, Rümelinstr. 23, D-72070, Tübingen, Germany

    J. E. Hoppe

Authors
  1. J. E. Hoppe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoppe, J.E. State of art in antibacterial susceptibility ofBordetella pertussis and antibiotic treatment of pertussis. Infection 26, 242–246 (1998). https://doi.org/10.1007/BF02962373

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02962373

Keywords

Search

Navigation